Ten years since the immune checkpoint inhibitor ipilimumab was approved for advanced
melanoma, it is time to reflect on the lessons learned regarding modulation of the immune …

Immune checkpoint inhibitors target the dysfunctional immune system, to induce cancer-cell
killing by CD8-positive T cells. Immune checkpoint inhibitors, specifically anti-CTLA4 and …

Background Whether pembrolizumab given both before surgery (neoadjuvant therapy) and
after surgery (adjuvant therapy), as compared with pembrolizumab given as adjuvant …

Background Neoadjuvant chemotherapy and radiation followed by surgical resection of the
rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is …

Background In a pilot study involving patients with cutaneous squamous-cell carcinoma, a
high percentage of patients had a pathological complete response with the use of two doses …

Background Neoadjuvant or adjuvant chemotherapy confers a modest benefit over surgery
alone for resectable non–small-cell lung cancer (NSCLC). In early-phase trials, nivolumab …

Neoadjuvant ipilimumab and nivolumab induces high pathologic response rates (pRRs) in
clinical stage III nodal melanoma, and pathologic response is strongly associated with …

Relatlimab and nivolumab combination immunotherapy improves progression-free survival
over nivolumab monotherapy in patients with unresectable advanced melanoma. We …

PURPOSE Neoadjuvant chemotherapy plus nivolumab has been shown to be effective in
resectable non–small-cell lung cancer (NSCLC) in the NADIM trial (ClinicalTrials. gov …

The gut microbiota shapes the response to immune checkpoint inhibitors (ICIs) in cancer,
however dietary and geographic influences have not been well-studied in prospective trials …